What Genesis Research does

Genesis Research Group, founded in 2009 and headquartered in Hoboken, New Jersey, is a private, PE-backed life sciences consulting firm that advises pharmaceutical, biotechnology, and medical device companies on real-world evidence (RWE), health economics and outcomes research (HEOR), and market access and pricing strategy. The firm operates three proprietary technology platforms: EVID AI (in-house evidence synthesis for literature reviews, systematic reviews, and surveillance), RPR/Rapid Payer Response (tech-enabled stakeholder insights from payers, KOLs, patient advocacy groups, and policy makers), and IEP (evidence planning). These platforms are delivered alongside a Flexible Integrated Teams (FIT) consulting model in which multidisciplinary Genesis personnel embed inside client organizations and adapt without statement-of-work adjustments.

The firm employs 200+ researchers, data specialists, and technology experts across offices in Hoboken (HQ), Newcastle, London, Fleet (UK), and Gurugram and Hyderabad (India), with leadership drawn from Biogen, GSK, and Elan. Its customer base includes marquee pharma logos (AbbVie, Bristol Myers Squibb, Pfizer, Roche, Novartis, Lilly, Sanofi, Janssen, Novo Nordisk) as well as biotech (Regeneron, Genmab, Akebia, Alkermes) and diagnostics (GE Healthcare), totaling 115 innovative companies supported. Revenue is generated primarily through professional services consulting engagements; the EVID AI platform was made available free of charge through December 31, 2026 in a freemium distribution move intended to convert platform users into paid consulting work. The company is backed by Rallyday Partners (since 2020) and has executed three acquisitions (Sirius Market Access 2020, Evid Science 2021, Market Access Transformation 2022) to build out market access, evidence synthesis, and AI capabilities. It maintains ISO 27001, Cyber Essentials Plus, GDPR, and CCPA certifications, and operates an industry-leading stakeholder network of 3,500+ vetted experts across 65+ countries.

Name

Genesis Research

Legal name

Genesis Research LLC

Website

https://genesisrg.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

Genesis Research Group is a PE-backed life sciences consulting firm that delivers real-world evidence, HEOR, and market access services to pharmaceutical, biotechnology, and medical device companies through proprietary platforms (EVID AI, RPR, IEP) and embedded Flexible Integrated Teams.

Ownership category

akta.pro rank

Product category

Life Sciences Consulting

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Engineering, Accounting, Research, Management (8700), Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

akta.pro secondary industries

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)

Keywords

• Real-world evidence services
• Health economics consulting
• Market access strategy
• Evidence synthesis solutions
• Life sciences consulting

Headquarters

HQ city

Hoboken

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Consulting and Professional Services: Genesis generates revenue through consulting engagements in real-world evidence, HEOR, market access, and evidence synthesis. Services are delivered through Flexible Integrated Teams (FIT) that adapt to client needs. The company also offers optional expert support for EVID AI platform users.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Genesis Research provides life sciences consulting services in real-world evidence (RWE), health economics and outcomes research (HEOR), and market access strategy, delivered through Flexible Integrated Teams (FIT) of 200+ researchers and supported by three proprietary technology platforms: EVID AI (evidence synthesis), RPR (rapid stakeholder insights), and IEP (evidence planning). The firm serves pharmaceutical, biotech, and medical device companies with services spanning evidence generation, market access strategy, payer engagement, pricing, and scientific communications across the product lifecycle.

Product overview

Genesis Research Group offers a platform-plus-services portfolio centered on three proprietary technology platforms (EVID AI for evidence synthesis, RPR for rapid payer/stakeholder insights, and IEP for evidence planning) supported by consulting service offerings in real-world evidence, HEOR, market access, evidence synthesis, stakeholder insights, and external control arms. The company operates a Flexible Integrated Teams (FIT) engagement model allowing clients to access expert multidisciplinary teams on demand. The portfolio is delivered through a global team of 200+ researchers across offices in North America, Europe, and Asia.

Differentiator

Problem solved

Functional benefit

Brands

• EVID AI: Full-spectrum AI-powered evidence synthesis platform for literature reviews, surveillance, and systematic reviews.
• RPR (Rapid Payer Response)
• IEP (Evidence Planning)
• FIT (Flexible Integrated Teams)

Products and services

• EVID AI In-house developed full-spectrum evidence synthesis platform that consolidates literature reviews, surveillance, and systematic reviews into a single structured environment for life sciences organizations. Supports rapid evidence questions, targeted literature reviews, formal SLR workflows, literature surveillance, competitive intelligence, disease landscape overviews, KOL identification, and evidence gap assessments. Made available free of charge through December 31, 2026 for approved life sciences organizations and eligible researchers.
• RPR (Rapid Payer Response) Technology-enabled platform for rapid stakeholder insights that enables agile development of market access strategies and fit-for-purpose evidence-generation plans. Provides access to payer, KOL, patient advocacy group, and policy maker insights across the product lifecycle, leveraging a global network of 3,500+ vetted stakeholders across 65+ countries.
• IEP (Intelligent Evidence Planning) Evidence planning platform that helps organize and optimize evidence generation strategies across product lifecycle stages for life sciences companies.
• Real-world Evidence (RWE) Services Strategic, data-agnostic approach to real-world evidence leveraging global datasets and expertise from early development to commercialization for life sciences companies.
• HEOR (Health Economics and Outcomes Research) Consulting Consulting services for health economics, outcomes research, and economic burden analysis supporting evidence generation and value demonstration for pharmaceutical and biotech clients.
• Market Access & Value Strategy Strategic advisory services for access and pricing, including US market access analytics and global pricing/reimbursement strategies for life sciences companies.
• Evidence Synthesis Services Comprehensive literature reviews, systematic reviews, and surveillance services for evidence generation across therapeutic areas for life sciences organizations.
• Stakeholder Insights Services Engagement with payers, KOLs, patient advocacy groups, and policy makers to test market access and evidence strategies through a vetted global stakeholder network.
• External Control Arms Services Services for developing and utilizing external control arms in clinical research and regulatory submissions for life sciences companies.
• FIT (Flexible Integrated Teams) Engagement Model Optional engagement model providing expert multidisciplinary teams that adapt to evolving research needs without requiring statement of work adjustments, serving as a trusted extension of client organizations across life sciences engagements.

Quantifiable outcome

• 115 innovative companies supported by the company's work
• +2 more outcomes

Named customers14 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• ISPORcoreGTM or Marketing Partner · 27 February 2025Genesis Research Group became an inaugural member of the ISPOR Corporate Partnership Program, demonstrating commitment to advancing health economics and outcomes research excellence. ISPOR is the leading professional society for health economics and outcomes research.
• SyapsecoreStrategic or Co-development Partner · 17 August 2022Strategic partnership with Syapse, a leading real-world evidence company dedicated to advancing real-world evidence for oncology. The partnership combines Genesis's RWE and market access expertise with Syapse's real-world data capabilities to offer comprehensive solutions to oncology innovators.
• Clinical Outcomes Solutions (COS)coreStrategic or Co-development Partner · 15 July 2022Innovative partnership with Clinical Outcomes Solutions, a COA (Clinical Outcomes Assessment) specialist. The partnership addresses the evolving regulatory landscape regarding RWE and provides clients with comprehensive evidence generation capabilities combining clinical outcomes assessment with RWE and HEOR.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Evidera: Evidera (part of Thermo Fisher Scientific/PPD) is one of the largest dedicated HEOR, RWE, and market access consultancies. Directly comparable to Genesis on service lines, customer base (top pharma), and technology-enabled evidence offerings, but at significantly greater scale and as part of a full-service CRO.
• Putnam Associates: Putnam Associates is a specialized strategy and market access consulting firm serving pharma, biotech, and MedTech. Comparable to Genesis on market access strategy, pricing, and payer evidence work, with a similarly focused delivery model for top-tier pharma clients.
• Analysis Group: Analysis Group is a leading private economics and strategy consulting firm with a large HEOR and health economics practice serving top pharma. Directly comparable on HEOR studies, payer research, and economic modeling for biopharma, with similar enterprise delivery model.
• Certara: Certara provides biosimulation, regulatory science, and real-world evidence software and services to pharma and biotech. Directly comparable to Genesis in evidence synthesis, regulatory-grade RWE, and technology-enabled drug development workflows, with strong technology overlap (modeling + EVID AI style evidence tools).
• Charles River Associates (CRA): CRA's Life Sciences practice provides HEOR, RWE, and pricing/market access consulting to pharma and biotech. Comparable to Genesis on study design, payer research, and value demonstration engagements, with similar reliance on senior PhD economists and health economists.

Broad incumbents

• ICON plc: ICON plc is a leading global CRO with significant RWE and HEOR capabilities post-PRA Health Sciences and Symphony Health integrations. Competes with Genesis for enterprise RWE engagements and is meaningfully larger and more diversified across trial execution and real-world data.
• Parexel International: Parexel is a major global CRO offering RWE, HEOR, and market access within full clinical and commercialization services. Comparable as a competitor for enterprise pharma RWE/HEOR work, particularly where sponsors want integrated Phase I–IV and evidence packages.
• IQVIA: IQVIA is the largest life sciences services and data company, offering RWE, HEOR, and market access alongside clinical, technology, and data assets. Competes with Genesis in RWE/HEOR engagements and on technology-enabled evidence platforms, with a much broader portfolio and integrated data infrastructure.

Emerging players

• PHMR (Veramed Group): PHMR is a specialized health economics and outcomes research consultancy serving pharma. Directly comparable on HEOR, market access, and evidence synthesis service lines, though materially smaller in scale and geographic reach than Genesis.
• Precision Medicine Group: Precision Medicine Group supports biotech and pharma with evidence, market access, and commercialization services. Comparable in HEOR/RWE offerings and customer overlap (mid-to-large biotech), but with broader commercialization scope including medical affairs and patient access services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/genesisheor?lang=en
• LinkedInlinkedin.com/company/genesisresearch
• Instagraminstagram.com/genesis.research

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Research